Production (Stage)
Inovio Pharmaceuticals, Inc.
INO
$2.22
-$0.05-2.20%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -19.69M | -19.38M | -25.17M | -32.24M | -30.47M |
Total Depreciation and Amortization | 743.50K | 775.80K | 765.90K | 828.60K | 759.70K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -3.15M | -327.00K | -184.30K | 1.42M | 1.80M |
Change in Net Operating Assets | -4.77M | -731.00K | -2.86M | 1.78M | -851.30K |
Cash from Operations | -26.87M | -19.66M | -27.44M | -28.21M | -28.76M |
Capital Expenditure | -59.40K | 0.00 | 0.00 | -452.30K | -35.60K |
Sale of Property, Plant, and Equipment | -- | 59.30K | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 7.60K | 34.59M | 14.08M | 10.42M | 45.42M |
Cash from Investing | -51.80K | 34.64M | 14.08M | 9.97M | 45.38M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | 0.00 | 0.00 | 0.00 | -16.42M |
Issuance of Common Stock | 1.10M | 13.08M | 667.10K | 17.13M | 5.23M |
Repurchase of Common Stock | -74.20K | 0.00 | -6.40K | -240.10K | -174.20K |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | 16.06M | 0.00 | 16.15M | -- |
Cash from Financing | 1.03M | 29.15M | 660.60K | 33.03M | -11.36M |
Foreign Exchange rate Adjustments | -- | 0.00 | 0.00 | 0.00 | 32.40K |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -25.90M | 44.13M | -12.70M | 14.79M | 5.29M |